Articles by The Lancet

COVID-19 vaccination potential won't be achieved without increased production, affordable pricing, global availability, and successful rollout

The first clinical efficacy results of the vaccine are based on a pre-specified pooled analysis of phase 3 trials in the UK and Brazil

Robust antibody and T-cell response seen in older adults is encouraging

Some low- and middle-income countries could see HIV, TB, and malaria deaths increase by as much as 10, 20, and 36 percent respectively over the next five years

The creation of an effective vaccine is seen as the long-term solution to controlling the COVID-19 pandemic

Person-to-person transmission of SARS-CoV-2 occurred between two people with prolonged, unprotected exposure while the first patient was symptomatic

A small observational study of women from Wuhan, China, showed no adverse outcomes in neonates or that the virus can pass to the child while in the womb

Analysis includes 99 patients with laboratory-confirmed 2019 novel coronavirus

Only 41 percent of clinical trial results are reported promptly onto the US trial registry, and one in three trials remain unreported, according to the first comprehensive study of compliance since new US regulations came into effect in January 2017

Tuberculosis can be treated, prevented, and cured, yet it kills 1.6 million people a year